Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionEngineers Gate Manager LP
Latest Disclosed Ownership11,198 shares
Latest Disclosed Value $ 1,475,225
Engineers Gate Manager LP reports 9.11% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Engineers Gate Manager LP filed a 13F-HR form disclosing ownership of 11,198 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $1,475,225 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 12,320 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -9.11% during the quarter. The current value of the position is $1,848,902 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,198 -1,122 -9.11 1,475 -15.57 0.0184
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,320 4,686 61.38 1,747 63.12 0.0207
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,634 2,242 41.58 1,072 58.20 0.0123
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,392 2,273 72.88 678 96.80 0.0084
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,119 -15,847 -83.55 345 -86.71 0.0058
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,966 -57,656 -75.25 2,589 -70.68 0.0451
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 76,622 41,978 121.17 8,828 85.11 0.1723
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,644 17,542 102.57 4,769 102.25 0.1076
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,102 7,487 77.87 2,359 86.26 0.0621
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,615 -13,205 -57.87 1,267 -50.68 0.0362
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,820 5,832 34.33 2,567 60.34 0.0949
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,988 -734 -4.14 1,602 -10.71 0.0606
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,722 13,625 332.56 1,794 266.67 0.0749
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,097 4,097 489 0.0294
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -5,262 -100.00 0 -100.00
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,262 1,539 41.34 513 46.99 0.0188
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,723 976 35.53 349 49.15 0.0137
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,747 -3,909 -58.73 234 -63.32 0.0105
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,656 -5,149 -43.62 638 -44.47 0.0364
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,805 11,805 1,149 0.0739
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -12,618 -100.00 0 -100.00
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,618 8,983 247.13 1,213 173.81 0.0569
2020-08-17 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,635 929 34.33 443 89.32 0.0225
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,706 -21,399 -88.77 234 -90.97 0.0169
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,105 18,635 340.68 2,591 425.56 0.1139
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,470 5,470 -77.31 493 -80.97 0.0250
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,400 -100.00 0 -100.00
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,400 2,400 211 0.0128
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.